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Obstetric trends show changes in complication rates and maternal characteristics such as
caesarean section, induced labour, and maternal age. To what degree such general time
trends and changing patterns of antiepileptic drug use influence pregnancies of women with
epilepsy (WWE) is unknown. Our aim was to describe changes in maternal characteristics
and obstetric complications in WWE over time, and to assess changes in complication risks
in WWE relative to women without epilepsy.
Methods
This was a nationwide cohort study of all first births in the Medical Birth Registry of Norway,
1999–2016. We estimated maternal characteristics, complication rates, and risks for WWE
compared to women without epilepsy. Main maternal outcome measures were hypertensive
disorders, bleeding in pregnancy, induction of labour, caesarean section, postpartum hem-
orrhage, preterm birth, small for gestational age, and epidural analgesia. Time trends were
analyzed by logistic regression and comparisons made with interaction analyses.
Results
426 347 first births were analyzed, and 3077 (0.7%) women had epilepsy. In WWE there
was an increase in proportions of induced labour (p<0.005) and use of epidural analgesia
(p<0.005), and a reduction in mild preeclampsia (p = 0.006). However, the risk of these out-
comes did not change over time. Only the risk of severe preeclampsia increased signifi-
cantly over time relative to women without epilepsy (p = 0.006). In WWE, folic acid
supplementation increased significantly over time (p<0.005), and there was a decrease in
smoking during pregnancy (p<0.005), but these changes were less pronounced than for
women without epilepsy (p<0.005).
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Conclusions
During 1999–2016 there were important changes in maternal characteristics and complica-
tion rates among WWE. However, outcome risks for WWE relative to women without epi-
lepsy did not change despite changes in antiepileptic drug use patterns. The relative risk of
severe preeclampsia increased in women with epilepsy.
Introduction
Epilepsy is one of the most common chronic diseases during pregnancy.[1–4] Women with
epilepsy (WWE) have been considered as high risk parturients with increased risk for maternal
complications.[2–8] Almost half of women with ongoing or previous epilepsy use antiepileptic
drugs (AEDs) in pregnancy to control seizures despite their potential adverse effects on the
fetus and maternal complications.[2, 9–11] The pattern of antiepileptic drug use in pregnant
WWE has changed markedly during the last two decades owing to newer antiepileptic drugs,
primarily lamotrigine and levetiracetam, replacing older antiepileptic drugs, such as carbamaz-
epine, phenytoin, and valproate. [12–14] The newer antiepileptic drugs are better tolerated
and believed to have less fetal and maternal adverse effects, but are associated with increased
seizure risk during pregnancy.[10, 11, 15–19] Increasing maternal age, increasing maternal
body mass index (BMI), and decrease in smoking during pregnancy over the last two decades
should also affect WWE.[20–23] These factors could be proportional or have a more complex
interaction. Global trends show an increase in caesarean section rates and increased induction
of labour.[24–26] Such interventions are common in WWE.[2, 4, 5, 7, 8] During the last
decade, there has been an increasing focus on management of WWE during pregnancy and
delivery and recent guidelines encourage close monitoring of pregnancies in WWE and strict
indications for interventions.[25, 27–30] However, there is little data on how focused manage-
ment and guidelines have affected maternal outcomes of WWE. A recent meta-analysis indi-
cates a trend towards increasing rates of caesarean section and induction of labour in WWE.
[31] However, different geographical populations with great variation in obstetric practice
were compared to describe differences over time, and no reference populations were included.
Therefore, it is not known how changes in population characteristics, obstetric practice and
general complication rates have affected WWE. We expect that changes during the recent
years in folate use, indications for operative interventions, and AEDs used have all influenced
maternal complications in WWE during pregnancy and when giving birth.
By analyzing a stable nationwide cohort over 18 years, our aim was to describe changes in
maternal characteristics and maternal complication rates in WWE over time, and to assess
changes in complication risks relative to women without epilepsy. For changes in outcome
risks in WWE over time, the influence of AED use and other specific factors were assessed.
Material and methods
This population-based, nationwide study used data from the Medical Birth Registry of Norway
(MBRN) from 1999 through 2016. Reporting to the MBRN is compulsory from all maternity
wards. All pregnancies from 12 weeks gestation are recorded. Data are prospectively registered
throughout pregnancy, delivery and postpartum period on a standardized form that has been
unchanged since 1999. All data are forwarded to the MBRN by the attending midwife or obste-
trician. Data includes maternal and paternal social factors, maternal health prior to and during
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pregnancy, complications and interventions during pregnancy and birth, perinatal outcome,
and complications in the children. The MBRN is routinely linked to the National Population
Database via a unique social security number, given to all citizens in Norway, to ensure notifi-
cation of all births in the country.[32]
Only first pregnancies were included and analyzed, excluding subsequent pregnancies from
the same women in order not to interfere with or dilute outcomes.[33] Only singleton
pregnancies� 22 weeks of gestation were included, thereby excluding multiple gestations
(1.8%). Women with missing social security number were also excluded (0.6%), representing
foreigners or immigrants without permanent residence.
Epilepsy was registered in a checkbox at the standardized form. Information on type of epi-
lepsy or seizure activity was not registered. The epilepsy diagnosis in MBRN has previously
been found to be correct in 92.3% of cases.[9] Information on AED use in pregnancy (identi-
fied by ATC classification) was recorded as written text with no information on dose or thera-
peutic changes throughout pregnancy. Registration of AED use in MBRN has previously been
found to be correct in 91.7% of cases.[33, 34] We identified and analyzed any AED use (all
AED use including both mono- and polytherapy treatment). We analyzed also all WWE with-
out any AEDs during their pregnancy. Furthermore, an a priori decision was made to analyze
the four most common AEDs in monotherapy. This was performed to obtain both homoge-
nous and large enough groups.
Time was examined as an effect measure modifier. The exposure of time was stratified
according to year of birth. To obtain large enough groups and to increase rare outcomes in
specified time categories, three subsequent years were merged into a total of six triennial time
categories; 1999–2001, 2002–2004, 2005–2007, 2008–2010, 2011–2013, and 2014–2016.
Main outcomes were; a compound variable of any hypertensive disorder, mild and severe
preeclampsia, bleeding in pregnancy, induction of labour at term, emergency and elective cae-
sarean sections, postpartum hemorrhage, spontaneous preterm birth, small for gestational age,
and epidural analgesia. Spontaneous preterm birth,< 37 weeks, (induction of labour and pre-
term elective caesarean sections were excluded from these analyses) was calculated from ultra-
sound assessment of due date. Last menstrual period was used for gestational age estimation in
2.3% of all births where ultrasound dates were missing. Mild preeclampsia was defined as per-
sisting blood pressure�140/90 mmHg combined with proteinuria� 0,3g per 24 hours. Severe
preeclampsia was defined as blood pressure�160/110mmHg, proteinuria�3 g per 24 hours,
oliguria or clinical symptoms of preeclampsia. Severe preeclampsia also included all cases of
early onset preeclampsia (<34 weeks), eclampsia, or HELLP syndrome (hemolysis, elevated
liver enzymes, low platelets). The compound variable of any hypertensive disorder was defined
as the presence of any of these hypertensive disorders or gestational hypertension. Superim-
posed preeclampsia in women with pre-gestational hypertension was not specified but was
included in the respective subcategories of hypertensive complications by severity. Bleeding in
pregnancy included any vaginal bleeding throughout pregnancy reported by health workers in
the primary care or in hospital. Induction of labour included induction at term (37–41 weeks),
regardless of method. Caesarean section was reported as either an elective or an emergency
procedure. Bleeding during delivery and within the next 24 hours after delivery (postpartum
hemorrhage) was reported as> 1500ml, and all caesarean deliveries were excluded. Small for
gestational age was defined as sex specific birthweight below the 2.5 percentile by gestational
age, using z-score of all first births. Epidural analgesia was registered as any use throughout
delivery. Other epilepsy core maternal outcomes suggested by the CROWN initiative were
either not properly addressed in the MBRN or severely underpowered for inclusion in our
study.[35] All outcomes were registered in checkboxes in the MBRN, except gestational age
and birthweight.
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Other variables were: mean maternal age, maternal employment status (employed or not),
maternal nationality (native Norwegian or other), marital status (married or cohabitant vs. sin-
gle), maternal pre-existing chronic disease (kidney disease, hypertension, diabetes mellitus),
early gestational BMI, any self-reported smoking during pregnancy, use of folic acid supple-
mentation in pregnancy (nationally recommended standard dose 0,4mg/day), and maternal
hospital stay in days. BMI was only available from the year 2006 and onwards.
Statistical analyses
We estimated total risk of all outcomes for WWE compared to women without epilepsy. Risks
of outcomes were estimated in WWE treatment subgroups i.e. all WWE, WWE without
AEDs, WWE with AEDs (any treatment in both mono- and polytherapy was included), and
WWE with the four most common AEDs in monotherapy.
Logistic regression was used to estimate odds ratios (ORs) and interaction with adjustment
for possible confounding by maternal age, smoking, folic acid supplementation and chronic
diseases (pre-existing hypertension, kidney disease, and diabetes mellitus) for all outcomes.
Adjustment by induction of labour and caesarean section was made where appropriate. Pla-
centa previa, vaginal bleeding in pregnancy, augmented contractions, maternal nationality,
and operative vaginal delivery were considered as possible confounders but not included in
the final models, as they did not change the estimates.
Adjusted average effects for the whole study period of having epilepsy on outcomes without
the effect of time were calculated and presented in tables. Time trends were then analyzed sep-
arately for WWE and women without epilepsy and interaction analyses were then used to
compare risk changes over time in WWE relative to women without epilepsy for maternal
characteristics and risk of outcomes. Thereafter, adjusted time trends and interactions were
estimated. The time varying effect on proportions and risk changes over time were further
explored in stratification-based sensitivity analyses. This was performed by analyzing time
trends and interactions repeatedly in strata of AEDs and covariates. To probe the interaction
in analyses, independently estimated adjusted ORs (aOR) for each triennial time category was
presented as graphs. In our analysis we put emphasis on estimates and their confidence inter-
vals. P-values are used to test for trends and differences in trends between WWE and women
without epilepsy.
All analyses were performed with IBM SPSS (Statistical Package for Social Sciences) version
24.0.
The study was approved by the Regional Ethics Committee of Western Norway (REK 2013/
186). Use of Norwegian national register data does not require consent from participants.
Results
A total of 426 347 women gave birth for the first time 1999–2016 (41.6% of all births within the
time period), of whom 3077 (0.7%) were WWE. The proportion of WWE was stable (0.7–
0.8%) until 2011, with a decrease to 0.5% thereafter (p<0.005). AEDs were used by 1200
(39.9%) WWE, and 1022 of them were on monotherapy during pregnancy. The total number
of WWE on AEDs was unchanged during the study period (p = 0.125). The four most com-
mon AEDs in monotherapy were lamotrigine (N = 437), carbamazepine (N = 243), valproate
(N = 130), and levetiracetam (N = 118). The pattern of AED use changed over time with
increasing use of lamotrigine and levetiracetam while the use of carbamazepine and valproate
decreased (p<0.005 for all) (S1 Fig).
In time trend analyses the proportion of induction of labour in WWE had the most notice-
able increase with a doubling from 11.9% in 1999–2002 to 26.7% in 2014–2016 (p<0.005) (Fig
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1). There was also an increase over time in the proportion of WWE with epidural analgesia
(p<0.005) and postpartum hemorrhage (p = 0.043). The proportion of any hypertensive com-
plications and mild preeclampsia decreased over time in WWE (p = 0.02 and P = 0.006 respec-
tively) as well as in the subgroup on AEDs.
Time trends in WWE were examined relative to time trends in women without epilepsy to
estimate change in risk of outcomes. The proportion of severe preeclampsia in WWE changed
from 2.0% to 3.6% during the study period. This increase was not significant (p = 0.39). In con-
trast, for the reference population without epilepsy the proportion of severe preeclampsia was
reduced from 2.3% to 1.5% (p<0.005). Consequently, the relative risk for severe preeclampsia
in WWE compared to women without epilepsy increased significantly over time (interaction
p = 0.006) (Fig 2).
In sensitivity analyses, this increase in relative risk for WWE did not change in parallel to
changes in any AED use or other covariates. Only when a combination of risk factors were
included (high maternal age, unemployed, single parent, smoking, and other chronic diseases),
the increase in relative risk of severe preeclampsia in WWE was reversed. Thus, the relative
increase in risk of severe preeclampsia in WWE was influenced by factors associated with
socioeconomic status. Fig 2 shows the aORs for all outcomes by three year periods (triennials)
with corresponding logistic regression interaction analyses for WWE compared to women
without epilepsy. Although there were significant changes in complications for both WWE
and women without epilepsy during the examined time period, the relative risk for WWE
Fig 1. Time trends for complications in women with epilepsy and women without epilepsy for first births, 1999–2016.
https://doi.org/10.1371/journal.pone.0225334.g001
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did not differ over time for the remaining parameters; any hypertensive disorder, mild pre-
eclampsia, induction of labour, emergency or elective caesarean section, preterm birth, bleed-
ing in pregnancy, postpartum hemorrhage, small for gestational age, and use of epidural
analgesia.
For WWE with lamotrigine monotherapy there was a borderline-significant reduction in
relative risk of elective caesarean sections compared to the reference population during the
study (interaction p = 0.06). WWE with lamotrigine also had a significant trend for increase in
proportion of induction of labour (p = 0.008). Relative risk estimates for WWE did not change
during the study period when changes in AED monotherapies or changes in other covariates
were included in the sensitivity analyses. The outcomes for the total study period for WWE
with and without AEDs are shown in Table 1, and for the four most common AEDs in mono-
therapy in S1 Table. WWE had increased risk for any hypertensive disorder (aOR = 1.24, 95%
CI: 1.09–1.41), mild preeclampsia (aOR = 1.35, 95% CI: 1.13–1.61), induction of labour
(aOR = 1.22, 95% CI: 1.10–1.35), elective caesarean section (aOR = 1.99, 95% CI: 1.73–2.29),
spontaneous preterm birth (aOR = 1.26, 95% CI: 1.08–1.47), and use of epidural analgesia
(aOR = 1.20, 95% CI: 1.12–1.29) compared to women without epilepsy. Induction of labour
was increased in WWE with lamotrigine (aOR = 1.55, 95% CI: 1.22–1.98) and levetiracetam
(aOR = 2.67, 95% CI: 1.78–4.02). All four AEDs were associated with increased risk of elective
caesarean section and epidural analgesia.
Maternal characteristics for the total study period are shown in S2 Table. There were signif-
icant changes in population characteristics in WWE during the registration period (Fig 3).
Time trends for maternal characteristics showed a lower decrease in proportion of smoking
Fig 2. Time trends for risks in women with epilepsy relative to women without epilepsy for first births, 1999–2016.
https://doi.org/10.1371/journal.pone.0225334.g002
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during pregnancy for WWE (24.3% to 10.9%) than for women without epilepsy (22.2% to
5.3%), thereby increasing the relative difference over time (interaction p<0.005). The use of
folic acid supplementation was more common in WWE than in women without epilepsy. The
proportion of supplementation increased over time in both groups (p<0.005), but the increase
was more pronounced in women without epilepsy (interaction p< 0.005). At the end of the
study period, folic acid use was equally common in both groups. The mean maternal age for
first births in WWE increased from 26.9 to 28.6 years from the first to the last triennial. This
increase did not differ between groups (interaction p = 0.096). Marriage rates were lower for
WWE than for women without epilepsy, and this difference increased during the study period
(interaction p = 0.041). Among WWE, there was also an increase in use of assisted reproduc-
tive technology while there was a reduction in mean birth weight, mean length of maternal
hospital stay and the proportion of native Norwegians.
Preterm births were in this study defined to include only spontaneous preterm births.
Therefore we analyzed separately all preterm births, including also those with induction of
labour and elective caesarean section (240 births in WWE and 26 139 births in women without
epilepsy). Induction of labour and elective cesarean are indicated more frequently in pregnan-
cies with various types of pathology. Our sub-analyses explored such associations. In all pre-
term births, WWE had an increasing proportion of severe preeclampsia from 11.6% in the first
time period to 34.6% in the last period (p = 0.01). During the study period the risk of severe
preeclampsia increased in WWE with preterm births relative to women without epilepsy with
preterm births (interaction p<0.005). In WWE with preterm births, there was no increased
risk for any other complications compared to preterm births in women without epilepsy.
BMI was only registered from 2006 and it was therefore not possible to account for this var-
iable across the complete study period or to properly estimate the effect of BMI on changes
over time. The BMI variable was also strained by missing values in 57% of cases after 2006.
Missing values did not differ between WWE and women without epilepsy. We did not find
any change in mean BMI 2006–2016, neither in WWE nor in women without epilepsy.
Table 1. Total complications in first pregnancies of women with epilepsy (WWE) with and without antiepileptic drugs (AED) compared to women without epilepsy
1999–2016.
Women without epilepsy WWE WWE without AED WWE with AED
423 270 3077 1877 1200
N (%) N (%) aOR N (%) aOR N (%) aOR
Any hypertensive disorder 29 231 (6.9) 270 (8.8) 1.24 (1.09–1.41) 160 (8.5) 1.18 (1.00–1.39) 110 (9.2) 1.33 (1.09–1.62)
Mild preeclampsia 12 445 (2.9) 129 (4.2) 1.35 (1.13–1.61) 73 (3.9) 1.22 (0.97–1.55) 56 (4.7) 1.55 (1.18–2.03)
Severe preeclampsia 7875 (1.9) 75 (2.4) 1.20 (0.95–1.52) 51 (2.7) 1.30 (0.98–1.72) 24 (2.0) 1.04 (0.69–1.56)
Induction of labour 53 203 (14.6) 477 (18.3) 1.22 (1.10–1.35) 239 (15.2) 0.98 (0.85–1.13) 238 (23.2) 1.61 (1.39–1.86)
Emergency cesarean section� 56 307 (13.3) 459 (14.9) 1.09 (0.99–1.21) 266 (14.2) 1.05 (0.92–1.20) 193 (16.1) 1.16 (0.99–1.36)
Elective cesarean section 15 572 (3.7) 220 (7.1) 1.99 (1.73–2.29) 127 (6.8) 1.86 (1.55–2.24) 93 (7.8) 2.19 (1.76–2.71)
Preterm birth 19 725 (6.0) 173 (7.9) 1.26 (1.08–1.47) 116 (8.3) 1.28 (1.06–1.55) 57 (7.2) 1.21 (0.92–1.59)
Bleeding in pregnancy 20 989 (5.0) 171 (5.6) 1.06 (0.91–1.24) 106 (5.6) 1.15 (0.94–1.40) 65 (5.4) 0.94 (0.73–1.21)
Postpartum hemorrhage 6963 (2.0) 61 (2.5) 1.29 (0.99–1.67) 32 (2.2) 1.12 (0.79–1.60) 29 (3.2) 1.54 (1.06–2.23)
Small for gestational age 7788 (1.8) 70 (2.3) 1.23 (0.97–1.56) 39 (2.1) 1.09 (0.80–1.51) 31 (2.6) 1.47 (1.03–2.10)
Epidural analgesia 181 531 (42.9) 1486 (48.3) 1.20 (1.12–1.29) 813 (43.3) 1.00 (0.92–1.12) 673 (56.1) 1.59 (1.42–1.79)
aOR = Adjusted odds ratio.
All outcomes adjusted for: maternal age, smoking, folic acid supplementation, chronic diseases.
�Also adjusted for induction of labour.
https://doi.org/10.1371/journal.pone.0225334.t001
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Discussion
The relative risk for severe preeclampsia increased in WWE from 1999 to 2016. However, the
proportion of severe preeclampsia in WWE did not change significantly during the study
period. The increased risk was attributed to a reduction in the reference population, women
without epilepsy. Although there was an increase in induction of labour and reduction in mild
preeclampsia in WWE, the risks of maternal complications did not change relatively over
time. This was regardless of increasing obstetric awareness of WWE during the study period
and fundamental changes in the pattern of AED use.
We report pronounced changes during the most recent years in maternal characteristics
and complication rates by a detailed examination of a complete, nationwide epilepsy popula-
tion, and also changes relative to those occurring in women without epilepsy. WWE represent
only 0.3–0.7% of all births.[1–4] Accordingly, large study samples and wide temporal intervals
are necessary to enable estimates of infrequent complications. In our study, we present a tem-
poral interval of 18 years. During this period, the occurrence of several maternal characteristics
and complications varied more over time among WWE than between the two compared
Fig 3. Time trends for maternal characteristics at first birth 1999–2016 in women with epilepsy and women without epilepsy.
https://doi.org/10.1371/journal.pone.0225334.g003
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groups, WWE and women without epilepsy (Fig 3). Accordingly, accurate present-day fre-
quencies differed markedly from the corresponding average for the total study period (pre-
sented in S2 Table). Although not all temporal changes were significant in interaction
analyses, additive changes appeared in such analyses. Therefore, temporal changes of charac-
teristics, outcomes and medication use are notable when estimating risks in WWE.
We report a concerning increase in risk of severe preeclampsia in WWE relative to women
without epilepsy. The increasing relative risk was especially evident in WWE with preterm
births. AED use and other specified covariates in our study could not explain this increase.
However, a combination of risk factors was important for the development of severe pre-
eclampsia in WWE. This is in accordance with a recent study on hypertensive pregnancy com-
plications in WWE.[34] Our findings emphasize a need for focused efforts on modifiable risk
factors, lifestyle and better health care for WWE to reduce the risk of severe preeclampsia.
Proportions with mild preeclampsia decreased in WWE during the study period. Mild pre-
eclampsia accounts for one-half of all hypertensive disorders, so the proportion of any hyper-
tensive disorder also declined. There is an apparent controversy in our findings as mild
preeclampsia became less common while the risk of severe preeclampsia increased over time
in WWE. However, mild and severer forms of preeclampsia are suggested to have different
pathophysiology with different factors influencing their development.[36] Therefore, factors
influencing mild and severe preeclampsia can develop differently over time. In women without
epilepsy, both mild and severe preeclampsia were reduced over time. Thus, the increase in risk
of severe preeclampsia is due to an epilepsy-specific effect. Proportions of induced labour
increased in WWE 1999–2016. However, the relative risk did not increase over time compared
to women without epilepsy. Thus, this increase does not represent an epilepsy-specific trend.
A previous meta-analysis studying maternal complications in WWE presented temporal
changes by comparing different geographical populations.[31] Without any reference popula-
tions, they reported an increase over time in caesarean section rates and induction of labour
for WWE. We found elective caesarean section to be more frequent in WWE than in women
without epilepsy, but without any increase over time. Nor was there any increase in proportion
of emergency caesarean section in WWE. In contrast, this proportion increased in women
without epilepsy but the difference in trends was not significant. A survey by the World Health
Organization has previously found increasing elective caesarean sections in first births as the
most important contributor to the increase in cesarean section rates in high-income countries.
[37] In our study, the proportion of elective caesarean sections declined in women without epi-
lepsy. Compared to other European countries Norway has a low total caesarean section fre-
quency.[22, 23] This applies also for WWE as the proportion of caesarean section was
considerably lower than previously reported for this group.[4, 7, 31] Despite our low baseline
proportion, WWE with AEDs had a trend for a further decrease of elective caesarean section,
in particular for WWE with lamotrigine treatment. WWE with lamotrigine at the same time
had an increase in induction of labour. The World Health Organization recommends
improved case selection for induction of labour to reduce caesarean section rates.[37] During
the study period, there has been an increase in focus on management of WWE during preg-
nancy and delivery in Norway illustrated by the numbers of studies, guidelines and consensus
reports. [2, 6, 8, 25, 27, 28, 30] Lamotrigine as monotherapy has increasingly been the pre-
ferred drug for WWE with well-controlled epilepsy.[38] WWE on lamotrigine have at the
same time more often been selected to induction of labour instead of a primary caesarean sec-
tion. These changes for WWE possibly indicate improved preconceptional management, as
suggested by these guidelines. We did not have any numerical measures or surrogate variables
to assess effects of an assumed professional development in the management of WWE during
the study period.
Obstetric time trends in women with epilepsy
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The proportion of WWE that smoked during pregnancy was halved. However, the decrease
among women without epilepsy was even greater, consequently increasing the relative differ-
ence at the end of the study period. Use of folic acid supplements among WWE increased
from 42% to 85% during the study period. However, the increase was even more pronounced
in women without epilepsy. These changes imply positive health effects for WWE over time,
but also room for improvement. Preconceptional counseling and focused personalized man-
agement is important for all WWE. The updated international EURAP cohorts of women with
epilepsy giving birth shows a similar increase in use of folic acid over time, but with consider-
ably lower absolute numbers, and therefore even more room for improvement.[39, 40]
WWE had longer hospital stays both after operative and vaginal deliveries compared to
women without epilepsy. The reduction from 4.7 to 3.5 days in WWE during the time period
was proportional to that seen in women without epilepsy, showing a persistent need for extra
postpartum care in WWE.
Strengths of our study are a complete nation-wide registration of all births in a large and
homogenous population. Exclusion of subsequent pregnancies ensures less dilution and interfer-
ence on outcomes, as outcome risks in later pregnancies change significantly, also in WWE.[33]
The diagnosis of epilepsy and AED use in the MBRN during pregnancy are reliable variables.[9,
33, 34] The standardized and unchanged registration, confirmed by the consistent time trends
for the reference population, makes certain that the temporal changes are true rather than inter-
nally administrative. Any changes in coding practice would be expected to affect WWE and the
reference population to the same degree. Outcomes registered in MBRN are precisely defined
enabling a detailed exploration. An ascertainment bias for epilepsy as a chronic disease cannot
be excluded. An ascertainment bias would entail more thorough registration in WWE possibly
increasing some unfavorable outcomes. However, precise definitions and national guidelines
should reduce this possibility.[25] Furthermore, several variables in the MBRN have been vali-
dated with acceptable to very good results. [34, 41–47] The total outcomes for WWE in our
study are in line with previous findings, indicating generalizability of our newly explored time
trends.[2, 4, 5, 7, 8] Being population based, the MBRN data does not suffer from referral bias.
However, WWE are at risk of early pregnancy terminations, consequently possibly excluding
some women with severe epilepsies from the actual birth cohort.[4, 48] As MBRN does not regis-
ter early pregnancies, we could not address this possible selection. An important limitation of
our study is the lack of data on seizure activity and type of epilepsy. Type of epilepsy and seizures
during pregnancy has previously not been associated with maternal pregnancy complications,
and epilepsy types are not expected to have changed 1999–2016.[9, 49] However, AED prescrip-
tion patterns changed fundamentally during the study. First line treatment for women in fertile
age is now more frequently lamotrigine and levetiracetam. These newer AEDs are associated
with higher seizure frequencies in pregnancy.[17–19] Females still treated with valproate and car-
bamazepine in the last years of the study period may have had more severe and treatment-resis-
tant epilepsies. Data on adverse effects of valproate in pregnancy increased during the study
period, culminating in the strengthened warning by the European Medicines Agency in 2014 on
the use of valproate in women of reproductive age.[50] WWE with AED monotherapy had low
numbers of most complications, and therefore our study lacks strength for some variables despite
the large cohort. BMI is an important covariate when exploring obstetric complications. The
BMI variable in the MBRN is strained in two dimensions: First, BMI was commenced in 2006.
Second, after commencing, the variable has high rates of missing values. We did not find any
change in BMI over time. This was unexpected considering previous knowledge on rising BMI
in populations.[51] Selection bias and high missing rates may explain this. However, it is likely
that BMI values should be accurate as measurements were made repeatedly during pregnancy.
Therefore, the effect of measured BMI on other variables should be reliable.
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The CROWN initiative suggested a set of core outcomes when conducting research on
WWE in pregnancy and childbirth. [35] Maternal outcomes not included in our study but sug-
gested by the CROWN initiative, were either not properly addressed in the MBRN or under-
powered for inclusion in our study.
Conclusions
Maternal complications in pregnancy and childbirth for WWE, developed similarly to that in
women without epilepsy from 1999 to 2016. Only the risk of severe preeclampsia increased
over time relative to women without epilepsy. Thus, neither the increased awareness of WWE
as a group with special needs nor the change in pattern of AED use lead to a reduction in com-
plications relative to women without epilepsy. There was a trend for a transition from elective
cesarean section to induction of labour, specific for WWE with lamotrigine treatment. The
increase in iatrogenic interventions for WWE indicate the need for continuous attention and
follow-up. Reduction in smoking and increased use of folic acid supplements in WWE were
positive factors, but the health care of WWE may still have room for improvement and benefit
from individual risk assessment and active preventive measures.
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